Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, Topics Dec 19 | 2025Altimmune Topline Ph2 Pemvidutide MASH DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 18 | 2025Lilly’s Ph3 ATTAIN-MAINTAIN Results; Orforglipron Filed; Novo Files Cagrisema and Receives FDA Warning Letter; Merck to Receive CNPV; SAB BIO Pivotal Ph2b T1DM Trial; Sagimet Enters Agreement for ResmetiromPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 17 | 2025Kailera Initiates H2H Study Vs. Semaglutide; Structure Initiates Ph1 Amylin Study; Rona Unveils Bivalent siRNA; Lilly Partners for Obesity Drug Discovery and Initiates Brenipatide Ph2 Bipolar Trial; Enveda Receives IND; ICER Obesity ReportPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 16 | 2025Pfizer FY 2026 Investor Call; Kailera Initiates Ph3 Obesity Program; Noom Biomarker Partnership; GLP-1RA Retinopathy LawsuitsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Dec 15 | 2025Lilly Initiates Eloralintide Ph3 Program; CKM Guidelines Published; New CagriSema Ph3 Peds Study; Noom Launches GLP-1RA Longevity ProgramPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Dec 15 | 2025FDA Leadership Pushes for Expedited Orforglipron Review; Novo and Cytokinetics Positive CHMP Opinions; Rezolute Misses Endpoints in Ph3 StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Dec 11 | 2025Zealand 2025 CMD and Partnership for Obesity Drug Discovery; Lilly Shares Topline Retatrutide Results; Corbus Topline CB1 Data; Dexcom Launches G7 15 Day CGM; Prolynx Series A Funding and Names CEOPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, SGLT2i, Topics Dec 10 | 2025Lilly Builds New Site in Alabama; Updated ADA/EASD 2026 Diabetes Guidelines; Novo Registers New Ph1 AssetPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Dec 09 | 2025Pfizer Acquires Oral GLP-1RA; FDA Grants AI Drug Development Tool in MASH; Lilly Discontinues Tempo; Novo Completes Akero Acquisition; Regeneron Registers siRNA Ph2 Study in DKD; December CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Dec 08 | 2025Structure’s Topline Ph2 Aleniglipron Data; Ascletis Reports Topline Data from Ph1 Oral GLP-1RA; BI Advances Triple Agonist for Obesity; Wave Announces Ph1 Data from Muscle-Sparing Asset; Lingo Now Available on Android; Medtronic Shifts Exec to MiniMedPurchase Blast
$599
Posted in: Insulin Delivery, Other, Topics Dec 04 | 2025Insulet O5 Algorithm Updates; BioAge Ph1 NLRP3i DataPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Dec 02 | 2025FDA Accepts AZ’s Baxdrostat NDA and MannKind’s sNDA for FUROSCIX in CHF + CKD; Medtronic Full US Launch for Abbott-Partnered CGM; Plozasiran Breakthrough Therapy Designation; New Fractyl Data; WHO Publishes GLP-1RA GuidelinesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 02 | 2025Lilly Cuts Zepbound Prices; Cagrisema Ph3 Pediatric Obesity Trial; Ascletis Selects Obesity Candidate; Altimmune Replaces CEO; Olazarsen Breakthrough Therapy Designation; New Ph3 Bofanglutide Study; Ikaria Registers Study for Obesity Asset Monotherapy and Combination with TirzepatidePurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i, Topics Nov 26 | 2025Novo Files 7.2mg Wegovy; CMS Cuts Semaglutide Prices; FDA Publishes Marketing Violation LettersPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other, SGLT2i, Topics Nov 25 | 2025Topline Amycretin Ph2 Data in T2DM; Abbott Libre 3/3+ CGM IssuesPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Nov 24 | 2025Novo Misses Alzheimer’s Endpoint; Merck’s New Ph1 Asset in T2DMPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Nov 21 | 2025Lilly and Novo Establish New Obesity Channels; Orforglipron CVOT Initiated; Lilly Ph2 Study in Chemo-Induced Nausea and Vomiting Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Topics Nov 20 | 2025Insulet Development and Commercial Roadmap; 2026 Investor EventPurchase Blast
$599
Posted in: Dual/triple agonist, Other, Topics Nov 20 | 2025Mazdutide Ph3 Topline Data; Novartis 2025 Investor Day Purchase Blast